Abraxane News and Research

RSS
The U.S. Food and Drug Administration approved Abraxane for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in January 2005 for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.
Genta announces preliminary results from study of Genasense Injection for advanced melanoma

Genta announces preliminary results from study of Genasense Injection for advanced melanoma

Press conference highlights emerging treatments in pancreatic cancer

Press conference highlights emerging treatments in pancreatic cancer

Abraxis BioScience reports $96.6 million net revenues for third quarter of 2009

Abraxis BioScience reports $96.6 million net revenues for third quarter of 2009

FDA grants Abraxis BioScience orphan drug designation for ABRAXANE

FDA grants Abraxis BioScience orphan drug designation for ABRAXANE

Abraxis Health dedicates its new manufacturing facility in Phoenix

Abraxis Health dedicates its new manufacturing facility in Phoenix

Abraxane prolongs survival in metastatic breast cancer

Abraxane prolongs survival in metastatic breast cancer

Two new clinical trials show promise for basal cell carcinoma and pancreatic cancer

Two new clinical trials show promise for basal cell carcinoma and pancreatic cancer

Study looks at breast-cancer drug called Abraxane for bladder cancer

Study looks at breast-cancer drug called Abraxane for bladder cancer

New York Times examines efforts to obtain FDA approval for Abraxane to treat earlier-stage cancer

New York Times examines efforts to obtain FDA approval for Abraxane to treat earlier-stage cancer

Key parameters for encapsulating drugs in nanoparticles

Key parameters for encapsulating drugs in nanoparticles

Herceptin-linked nanoparticles for targeted cancer therapy

Herceptin-linked nanoparticles for targeted cancer therapy

Advancing nanoparticle-based imaging and therapy of brain cancer

Advancing nanoparticle-based imaging and therapy of brain cancer

Nano-enabled drug discovery solutions will generate revenues of $1.3 billion in 2009

Nano-enabled drug discovery solutions will generate revenues of $1.3 billion in 2009

Launch date announced for Abraxane to treat metastatic breast cancer

Launch date announced for Abraxane to treat metastatic breast cancer

Abraxane, first in a new class of albumin-bound nanotechnology for the treatment of metastatic breast cancer

Abraxane, first in a new class of albumin-bound nanotechnology for the treatment of metastatic breast cancer

FDA approves Abraxane for metastatic breast cancer

FDA approves Abraxane for metastatic breast cancer

Investigational drug Abraxane is active and well tolerated in women with metastatic breast cancer

Investigational drug Abraxane is active and well tolerated in women with metastatic breast cancer

FDA approval for Cladribine to treat active Hairy Cell Leukemia

FDA approval for Cladribine to treat active Hairy Cell Leukemia